Independent Research
SMMT Analysis
6 pieces of research on Summit Therapeutics Inc.. We find the signal management buried in the earnings call.
5signal analyses
1news briefs
latest: Nov 17, 2026
Signal Analysis (3)
Analysis
Summit Therapeutics' Lung Cancer Drug Rejected by FDA
FDA rejected Summit Therapeutics' ivonescimab BLA for lung cancer because progression-free survival improvements do not establish effectiveness without overall …
Read analysis →Analysis
Summit Therapeutics Trades Below AstraZeneca's $18.36
AstraZeneca's $2 billion investment in Summit Therapeutics at $18.36 per share is now worth less on paper, with the stock trading at $14.63 as 26.3% short inter…
Read analysis →Analysis
Summit Therapeutics Phase III Beats Keytruda, Burns $458M
Summit Therapeutics' ivonescimab achieved Phase III superiority over pembrolizumab in non-small cell lung cancer, posting 30.8 months median overall survival ve…
Read analysis →